Common use of Additional Issuances Clause in Contracts

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or its Subsidiaries or other equity interest in the Company except as described on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or its Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d), or the Reports. The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock 's common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or its Subsidiaries or other equity interest in any of the subsidiaries of the Company except as described on Schedule 5(d). The Common Stock and all other equity of the Company and its Subsidiaries on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s 's Common Stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock Common Stock or equity of the Company or its Subsidiaries or other equity interest in the Company except as set forth in the Transaction Documents and as described in the Reports or on Schedule 5(d). The Common Stock of the Company on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] preceding the First Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock 's common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or its Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d), or in the Reports. The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or its Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d7(d). The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] trading day preceding the Initial Closing Date is set forth on Schedule 5(d7(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or its Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d7(d). The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] trading day preceding the Closing Date hereunder is set forth on Schedule 5(d7(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or its Subsidiaries or other equity interest in any of the Subsidiaries (if any) of the Company except as described on Schedule 5(d), or the Reports. The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock 's common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or its Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as described on Schedule 5(d), or the Reports. The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] trading day preceding the Closing Date is set forth on Schedule 5(d).

Additional Issuances. There are no outstanding agreements or preemptive or similar rights affecting the Company’s Common Stock common stock or equity and no outstanding rights, warrants or options to acquire, or instruments convertible into or exchangeable for, or agreements or understandings with respect to the sale or issuance of any shares of common stock or equity of the Company or its Subsidiaries or other equity interest in any of the Subsidiaries of the Company except as provided for under the SVI Related Transactions or as described on Schedule 5(d4(d). The Common Stock stock of the Company on a fully diluted basis outstanding as of the last Business Day [as defined in Section 13(p)] trading day preceding the Closing Date is set forth on Schedule 5(d4(d).